Transactions in Connection with Share Buy-back Program
24 juin 2024 09h55 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18 juin 2024 14h45 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The...
Transactions in Connection with Share Buy-back Program
17 juin 2024 09h33 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
12 juin 2024 15h45 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
11 juin 2024 14h50 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions in Connection with Share Buy-back Program
10 juin 2024 10h18 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
05 juin 2024 12h51 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 05, 2024Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate...
Transactions in Connection with Share Buy-back Program
03 juin 2024 09h09 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 3, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5...
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
03 juin 2024 09h00 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 3, 2024 Results from innovaTV207 evaluating tisotumab vedotin, showing 32.5% confirmed objective response rate in patients with recurrent or metastatic HNSCC,...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
02 juin 2024 17h30 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; June 2, 2024 Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received...